Results 21 to 30 of about 567,668 (313)
Observations on sleep-disordered breathing in idiopathic Parkinson's disease. [PDF]
PLoS ONE, 2014 BACKGROUND: This study has two main goals: 1.) to determine the potential influence of dopaminergic drugs on sleep-disordered breathing (SDB) in Parkinson's disease (PD) and 2.) to elucidate whether NREM and REM sleep differentially impact SDB severity ...
Philipp O Valko +4 more
doaj +1 more source
Alʹmanah Kliničeskoj Mediciny, 2023 The priority treatment approach for prolactinomas is therapy with dopamine agonists, which allows for elimination of clinical symptoms, normalization of prolactin levels, reduction of the adenoma size and prevention of metabolic abnormalities in the ...
Irena A. Ilovayskaya, Gulnar R. Vagapova
doaj +1 more source
Impulsivity in Patients with Parkinson’s Disease [PDF]
Journal of Biomedical & Clinical Research, 2017 In recent years focus has been increasingly placed on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD). ICDs include pathological attraction to gambling, compulsive shopping, compulsive eating and compulsive sexual behaviour and
Rumyana Kuzmanova +2 more
doaj +3 more sources
Predictors of dopamine agonist resistance in prolactinoma patients
BMC Endocrine Disorders, 2020 Background Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we
Elle Vermeulen +6 more
doaj +1 more source
Clinical Aspects and Management of Levodopa-Induced Dyskinesia
Parkinson's Disease, 2012 In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias.
Nicola Tambasco +7 more
doaj +1 more source
Dopamine Agonists: From the 1970s to Today
Neuroendocrinology, 2019 The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas. Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting ...
R. Auriemma +4 more
semanticscholar +1 more source
Dopamine Agonists and Impulse Control Disorders: A Complex Association
Drug Safety, 2017 Impulse control disorders (ICDs) are a well-known adverse effect of dopamine agonists (DAAs). This critical review aims to summarize data on the prevalence and factors associated with the development of an ICD simultaneous to DAA use.
M. Grall-Bronnec +8 more
semanticscholar +1 more source
Dopamine agonists and antipsychotics [PDF]
European Journal of Endocrinology, 2020 There can potentially be a number of clinical interactions that could adversely affect patient outcomes in a patient with a prolactinoma and psychiatric disease that might require antipsychotic and dopamine agonist treatment. Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size
openaire +2 more sources
PLoS ONE, 2019 Schizophrenia and Parkinson's disease can be controlled with dopamine antagonists and agonists. In order to improve the understanding of the reaction mechanism of these drugs, in this investigation we present a quantum chemical study of 20 antagonists ...
Ana Martínez +2 more
doaj +1 more source